Current Report Filing (8-k)
27 June 2017 - 7:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
Current Report
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event Reported): June 23, 2017
HISTOGENICS CORPORATION
(Exact Name of Registrant as Specified in its Charter)
|
|
|
|
|
Delaware
|
|
001-36751
|
|
04-3522315
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
830 Winter Street, 3rd Floor
Waltham, Massachusetts 02451
(781) 547-7900
(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
|
|
|
|
|
|
Emerging growth company
|
|
☒
|
|
|
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.01.
|
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
|
On
June 23, 2017, Histogenics Corporation (the Company) received a letter from the Listing Qualifications department of The NASDAQ Stock Market LLC (NASDAQ) notifying the Company that its application to transfer its common
stock from the NASDAQ Global Market to the NASDAQ Capital Market had been approved. The Companys common stock will be transferred to the Nasdaq Capital Market at the opening of business on June 30, 2017 and will continue to trade under
the symbol HSGX. This move to the NASDAQ Capital Market will not affect the trading of the Companys common stock. The NASDAQ Capital Market is a continuous trading market that operates in substantially the same manner as the NASDAQ
Global Market, but with less stringent listing requirements.
As previously announced, on May 16, 2017, the Company received a notice from NASDAQ
indicating that the Company no longer complies with the requirements of NASDAQ Marketplace Rule 5450(b)(1)(A) for continued listing on The NASDAQ Global Market because the Companys stockholders equity has fallen below $10 million as
reported on its quarterly report on Form 10-Q for the period ended March 31, 2017. In lieu of seeking to regain compliance for continued listing on the NASDAQ Global Market, the Company applied to transfer the listing of its common stock to the
NASDAQ Capital Market. Because the Company transferred its common stock listing from the NASDAQ Global Market to the NASDAQ Capital Market, the Company meets all the applicable requirements for initial listing on the NASDAQ Capital Market.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
Date: June 26, 2017
|
|
|
|
HISTOGENICS CORPORATION
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Adam Gridley
|
|
|
|
|
|
|
Adam Gridley
|
|
|
|
|
|
|
President and Chief Executive Officer
|
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From Apr 2024 to May 2024
Histogenics (NASDAQ:HSGX)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Histogenics Corporation (NASDAQ): 0 recent articles
More Histogenics Corp News Articles